| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 717-726, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
BA Lessey, S Albelda, CA Buck, AJ Castelbaum, I Yeh, M Kohler and A Berchuck
Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia.
Integrins are ubiquitous cell adhesion molecules that are involved in maintaining normal tissue morphology and have been implicated in the behavior of certain malignancies. We examined the expression of nine integrin subunits in 38 endometrial adenocarcinomas using immunohistochemistry. The pattern of integrin expression in the cancers was compared with that seen in the endometrium of 20 normal cycling women and 7 postmenopausal women. Integrin expression was correlated with grade, stage, nodal status, depth of invasion, steroid receptor status, and histological pattern. In endometrial cancers there was an inverse relationship between the number of integrins expressed and histological grade (P = 0.011). Of the normally expressed, constitutive endometrial epithelial integrin subunits (alpha 2, alpha 3, alpha 6, and beta 4), the least frequently seen in the cancers was the alpha 3 subunit (44.7%) and the most frequently found was alpha 6 (81.6%). The alpha 5 beta 1 integrin, a fibronectin receptor normally found only on endometrial stromal cells, was seen in 17.8% of cases of these epithelial cancers. In addition, a significant association was found between the loss of the alpha 2 beta 1 integrin and the presence of lymph node metastases (P < 0.001). These data suggest that a decline in integrin expression occurs more frequently in poorly differentiated endometrial cancers and that the loss of specific integrins may be associated with metastatic nodal spread.
This article has been cited by other articles:
 |
|
 |
|
  M. Lovecchio, E. Maiorano, R. A. Vacca, G. Loverro, M. Fanelli, L. Resta, S. Stefanelli, L. Selvaggi, E. Marra, and E. Perlino {beta}1C Integrin Expression in Human Endometrial Proliferative Diseases Am. J. Pathol., December 1, 2003; 163(6): 2543 - 2553. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Vacca, E. Marra, G. Loverro, E. Maiorano, A. Napoli, M. Lovecchio, L. Selvaggi, and E. Perlino Differential Expression of {beta}1c Integrin Messenger Ribonucleic Acid and Protein Levels in Human Endometrium and Decidua during the Menstrual Cycle and Pregnancy J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 720 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Park, T. Inoue, M. Ueda, T. Hirano, T. Higuchi, I. Konishi, H. Fujiwara, and S. Fujii Anti-CD9 monoclonal antibody-stimulated invasion of endometrial cancer cell lines in vitro: possible inhibitory effect of CD9 in endometrial cancer invasion Mol. Hum. Reprod., August 1, 2000; 6(8): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adachi, T. Taki, M. Higashiyama, N. Kohno, H. Inufusa, and M. Miyake Significance of Integrin {{alpha}}5 Gene Expression as a Prognostic Factor in Node-negative Non-Small Cell Lung Cancer Clin. Cancer Res., January 1, 2000; 6(1): 96 - 101. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Castelbaum, L. Ying, S. G. Somkuti, J. Sun, A. O. Ilesanmi, and B. A. Lessey Characterization of Integrin Expression in a Well Differentiated Endometrial Adenocarcinoma Cell Line (Ishikawa) J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 136 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Davis, I. Rabinovitz, B. W. Futscher, M. Schnolzer, F. Burger, Y. Liu, M. Kulesz-Martin, and A. E. Cress Identification of a Novel Structural Variant of the alpha 6 Integrin J. Biol. Chem., July 6, 2001; 276(28): 26099 - 26106. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
